Sun
L, Hsu
M, Cohen
RB, Langer
CJ, Mamtani
R, Aggarwal
C. Association between
KRAS variant status and outcomes with first-line immune checkpoint inhibitor–based therapy in patients with advanced non–small-cell lung cancer.
JAMA Oncol. Published online April 15, 2021. doi:
10.1001/jamadermatol.2021.0546Google Scholar